Zhangzhou Pientzehuang Pharmaceutical (600436) H2 2024 earnings summary

Executive summary

• Revenue increased 7.06% year-over-year, driven by stronger market planning and expanded sales channels, with core products showing notable sales growth.

• Net profit attributable to shareholders rose 6.32% year-over-year, with adjusted net profit (excluding non-recurring items) up 6.62%.

• Excluding the pharmaceutical distribution segment, revenue grew 13.29% year-over-year, offsetting declines in that segment.

Financial highlights

• Operating income reached RMB 1,076,892,660, up from RMB 1,005,849,730, a 7.06% increase year-over-year.

• Operating profit was RMB 356,658,220, up 5.10% year-over-year.

• Net profit attributable to shareholders was RMB 297,419,820, up 6.32% year-over-year.

• Basic EPS was RMB 4.93, up 6.25% year-over-year.

• Total assets at year-end were RMB 1,747,511,400, up 2.31% from the start of the year.

Outlook and guidance

• Plans to closely monitor raw material price trends and industry policy changes, strengthen risk management, and improve cost efficiency to support future profitability.